1	A comprehensive evaluation of an artificial intelligence based digital
2	pathology to monitor large-scale deworming programs against soil-
3	transmitted helminths: a study protocol
4	
5	Peter K. Ward ^{1,2,3¶*} , Sara Roose ^{1¶} , Mio Ayana ⁴ , Lindsay A. Broadfield ² , Peter Dahlberg ² , Narcis
6	Kabatereine ⁵ , Adama Kazienga ¹ , Zeleke Mekonnen ⁴ , Betty Nabatte ⁵ , Lieven Stuyver ⁶ , Fiona
7	Vande Velde ¹ , Sofie Van Hoecke ³ , Bruno Levecke ¹ *
8	
9	¹ Department of Translational Physiology, Infectiology and Public Health, Ghent University,
10	Merelbeke, Belgium
11	² Enaiblers AB, Uppsala, Sweden
12	³ IDLab, Department of Electronics and information systems, Ghent University – Imec,
13	Zwijnaarde, Belgium
14	⁴ Institute of Health, Jimma University, Jimma, Ethiopia
15	⁵ Vector Borne and Neglected Tropical Diseases Division, Ministry of Health, Kampala, Uganda
16	⁶ Scientific Advisor
17	
18	[¶] These authors contributed equally to this work.
19 20	* Corresponding authors. Email: <u>Bruno.levecke@UGent.be</u> (BL), <u>peter.ward@enaiblers.com</u> (PKW)
21	
22	
23	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Background: Manual screening of a Kato-Katz (KK) thick stool smear remains the current 26 standard to monitor the impact of large-scale deworming programs against soil-transmitted 27 helminths (STHs). To improve this diagnostic standard, we recently designed an artificial intelligence based digital pathology system (AI-DP) for digital image capture and analysis of 28 29 KK thick smears. Preliminary results of its diagnostic performance are encouraging, and a 30 comprehensive evaluation of this technology as a cost-efficient end-to-end diagnostic to 31 inform STH control programs against the target product profiles (TPP) of the World Health 32 Organisation (WHO) is the next step for validation.

33 Methods: Here, we describe the study protocol for a comprehensive evaluation of the AI-DP 34 based on its (i) diagnostic performance, (ii) repeatability/reproducibility, (iii) time-to-result, 35 (iv) cost-efficiency to inform large-scale deworming programs, and (v) usability in both 36 laboratory and field settings. For each of these five attributes, we designed separate 37 experiments with sufficient power to verify the non-inferiority of the AI-DP (KK2.0) over the manual screening of the KK stool thick smears (KK1.0). These experiments will be conducted 38 39 in two STH endemic countries with national deworming programs (Ethiopia and Uganda), 40 focussing on school-age children only.

Discussion: This comprehensive study will provide the necessary data to make an evidencebased decision on whether the technology is indeed performant and a cost-efficient end-toend diagnostic to inform large-scale deworming programs against STHs. Following the protocolized collection of high-quality data we will seek approval by WHO. Through the dissemination of our methodology and statistics, we hope to support additional

- 46 developments in AI-DP technologies for other neglected tropical diseases in resource-limited
- 47 settings.
- 48

49 Trial registration

50 The trial was registered on Clinicaltrials.gov (ID: NCT06055530).

51 Author summary

52 Millions of deworming tablets are annually administered to children to reduce the morbidity caused by intestinal worms. To monitor the progress of these large-scale deworming 53 54 programs, periodic assessments are made regarding the occurrence and prevalence of 55 intestinal worm infections. Manual examination of a stool smear through a compound 56 microscope remains the current diagnostic standard. We recently developed a device that 57 utilizes artificial intelligence (AI) to scan smears and recognize eggs of intestinal worms. 58 Encouraging preliminary results of the diagnostic performance warrant additional and more 59 research, essential for obtaining necessary approvals to support wide-scale adoption. 60 Here, we describe the study protocols we will employ for a comprehensive evaluation of this 61 Al-based device. The generated results will provide health decision-makers with evidence-62 based data to assess whether the tool can be recommended for informing large-scale 63 deworming programs against intestinal worms. Additionally, we provide full access to our

64 study documentation which may be relevant for evaluating other AI-based devices for 65 intestinal worms.

66 Introduction

67 Soil-transmitted helminths (STHs) are a group of intestinal roundworms transmitted through 68 the uptake of infectious life stages in the environment (often soil, referring to their common 69 name) [1, 2]. STHs, including the giant round worm (Ascaris lumbricoides), whipworm (Trichuris trichiura) and hookworms (Necator americanus and Ancylostoma duodenale), 70 71 primarily affect impoverished communities in (sub)tropical countries [1-3]. It was estimated 72 that 24% of the global population is affected by at least one of these STHs, resulting in a total 73 loss of 1.9 million disability-adjusted life years in 2019 [4, 5]. In response to this public health 74 issue, many STH-endemic countries have implemented national school-based deworming 75 programs, providing periodic oral anthelminthic treatment to the children at the schools in 76 the program [6-8]. The pharmaceutical industry's contribution of more than 6.5 billion 77 anthelmintic tablets for at-risk populations since 2016 has undoubtedly contributed to 78 reducing the disease burden in various STH-endemic countries [9, 10].

Encouraged by this progress, World Health Organization (WHO) has published its roadmap for STHs for the next decade (2020 – 2030), encompassing six ambitious targets (**Table 1**) [7, 11]. To advance towards the first two targets, it will be critical to periodically assess the STH infection prevalence, of both any intensity and moderate-to-heavy intensity (MHI) infections. The prevalence of any intensity STH infection is deployed as a parameter to determine the frequency of deworming (**Target #2**), while the elimination as a public health problem is defined when prevalence of MHI infections is less than 2% (**Target #1**) [7].

Table 1. The six 2030 targets and corresponding milestones put forward by the WHO [7].

Target		Milestone
#1	Achieve and maintain elimination of STH morbidity in pre- school-aged and school-aged children	98 countries with <2% children with MHI infections
#2	Reduce the number of tablets needed for large-scale deworming programs for STHs	50% reduction
#3	Increase domestic financial support to deworm STHs	25 countries deworming children by domestic funds
#4	Establish an efficient STH control program in adolescent, pregnant and lactating women of reproductive age	Coverage equals 75%
#5	Establish an efficient strongyloidiasis control program in school-aged children	75% of the children at risk of <i>Strongyloides</i> receiving ivermectin
#6	Ensure universal access to at least basic sanitation and hygiene by 2030 in STH-endemic areas	Reduce open defecation to 0%

87

86

88 Microscopic examination of a stool smear using the Kato-Katz (KK) thick smear technique and 89 manual counting of STH eggs remain the recommended diagnostic standard for epidemiological surveys designed to inform large-scale deworming programs [7, 12, 13]. 90 While KK thick smear is the sole diagnostic method mentioned in the 2030 targets for STHs 91 92 [7], this diagnostic tool has some significant pitfalls: test results are prone to human error; it 93 lacks clinical sensitivity when the intensity of infections is low, and hookworm eggs disappear when smears are not examined within 1h following preparation of the smear [14-17]. Within 94 95 the last two decades, a variety of alternative diagnostic tools have been developed or 96 repurposed, and subsequently evaluated for the diagnosis of STH infections in children [13, 97 18-21]. Despite improved clinical sensitivity for some diagnostic tools [15, 16], their 98 integration into national deworming programs has been challenging due to labour-intensive 99 procedures and resource demands [22]. Furthermore, as programs progress toward STH 100 control and elimination, clinical specificity becomes increasingly more important [23]. Indeed, 101 in the WHO's target product profiles (TPPs) for new diagnostic tools to monitor large-scale 102 deworming programs against STHs, the clinical sensitivity can drop to 60%, while the clinical 103 specificity should be at least 94% [24]. The high clinical specificity of KK thick smear (\geq 95) [16,

104 25, 26] remains a strong advantage, reinforcing its likely role as a reference diagnostic for the 105 next decade. While KK thick smear is likely to remain crucial, ongoing research and 106 innovations in diagnostic technology show promise to address its limitations and contribute 107 to more effective STH monitoring and control strategies [27, 28].

108 A clear opportunity lies in the automation of the egg counting, the step which is most prone 109 to human error, laborious and time-demanding (egg counting takes 80% of the time-to-result, 110 including data entry) [22]. We prototyped a proof-of-concept artificial intelligence-based 111 digital pathology (AI-DP) device and demonstrated it for automated scanning and detection 112 of STH eggs in KK thick smears [27]. Today, this AI-DP offers (i) electronic data capturing (EDC), (ii) whole slide imaging (WSI), (iii) an AI model and according AI development pipeline, (iv) AI 113 114 results verification, and (v) a cloud-based reporting and monitoring dashboard that can be 115 integrated into existing health systems (see also Fig 1). With encouraging preliminary results 116 and field testing, a comprehensive prospective, in-the-field evaluation of the AI-DP is urgently 117 needed to provide the necessary data for health decision makers to make an evidence-based 118 decision on whether this technology can be recommended to inform large-scale deworming 119 programs against STHs.

120 Here, we describe the study protocol for a comprehensive evaluation of an AI-DP based on its 121 (i) diagnostic performance, (ii) repeatability/reproducibility, (iii) time-to-result, (iv) cost-122 efficiency to inform large-scale deworming programs, and (v) usability both in a laboratory 123 and field setting. For each of these five attributes, separate experiments were designed to 124 test the hypothesis that the AI-DP (KK2.0) is non-inferior when compared to the manual 125 screening of the KK smears (KK1.0). The field work will be conducted in two STH endemic 126 countries with a national deworming program (Ethiopia and Uganda), focussing on school-127 age children (SAC) only. Through the dissemination of our methodology and statistics, we also

hope to support additional developments in any AI-DP technologies for other neglectedtropical diseases in resource-limited settings.

130

131 Methods

132 **1** Ethics statement

133 The study protocol will be submitted to the institutional review boards of the Faculty of 134 Medicine and Health Sciences of Ghent University (Belgium), the Health Institute of Jimma 135 University (Ethiopia), the Vector Control Division Research Ethics committee (Uganda), and 136 the Uganda National Council of Science and Technology for both review and approval. 137 Parent(s)/guardian(s) of the participants will sign an informed consent document indicating 138 that they understand both the purpose, and the procedures required for the study, and that 139 they are willing to have their child participate in the study. If the child is ≥ 6 years old, he/she will have to orally assent to participate in the study. Participants \geq 8 years old (\geq 12 years old 140 in Ethiopia) will only be included if they sign an assent form indicating that they understood 141 142 both the purpose of the study and the procedures required for the study, and they are willing 143 to participate in the study. Every child that tests positive on KK1.0 or whose stool sample 144 undergoes the egg spiking procedure will receive a single oral dose of 400 mg albendazole or 145 500 mg mebendazole in case of STH infections, and 40 mg/kg body weight praziguantel in 146 case of Schistosoma mansoni infections. If the presence of eggs other than STHs and S. 147 mansoni is confirmed, children will be referred to the nearest health centre.

The use of collected data will be strictly limited to the research objectives outlined in this study, and to enhance the accuracy and reliability of the AI diagnostic tool in identifying and diagnosing STHs. The study will adhere to the highest ethical standards, ensuring participant

- 151 privacy and data protection. All data will be treated with strict confidentiality, and measures
- 152 will be implemented to anonymize the data to ensure participant anonymity.

Study population and study sites 2 153

- 154 The study will focus on SAC (age 5 - 14) only, since they are the major target of large-scale
- deworming programs against STHs [6]. We will apply the inclusion and exclusion criteria 155
- 156 summarized in Table 2. These criteria have been adapted from criteria standardized and
- 157 applied throughout a series of drug efficacy trials [29].

Table 2. Inclusion and exclusion criteria that will be endorsed during the recruitment of 158

159 participants (adapted from [29]).

Inclusion criteria	Exclusion criteria
 Subject, male or female, is 5-14 years of age Parent(s)/guardian(s) of subject signed an informed consent document indicating that they understand the purpose and procedures required for the study and that they are willing to have their child participate in the study Subject of ≥6 years old has orally assented to participate in the study Subject of ≥8 (Uganda) / ≥12 (Ethiopia) years old has signed an assent form indicating that they understand the purpose of the study and procedures required for the study* Subject has provided a stool sample of minimum 5 grams 	 Subject has active diarrhoea (defined as the passage of 3 or more loose or liquid stools per day) Subject is experiencing a severe concurrent medical condition or has an acute medical condition Subject has received anthelmintic treatment within 90 days prior to the start of the study

¹⁶⁰ *These differences in inclusion criteria are due to differences in national policies.

162 The study will be conducted in both Ethiopia and Uganda. The selection of these countries 163 and the corresponding partners (Ethiopia: Jimma University; Uganda: Vector Control and 164 Neglected Tropical Diseases Division, Ministry of Health of Uganda) were based on ongoing 165 collaborations [20, 29-36], the presence of an STH control program (Ethiopia: since 2015; 166 Uganda: since 2003), and the availability of recent data on both the prevalence and intensity of STH infections [31, 32, 37]. Finally, both countries operate differently, allowing AI-DP 167 evaluation in a fully equipped laboratory (Jimma University, Ethiopia) and a field setting (VCD, 168 169 Uganda) that best mimic monitoring and evaluation (M&E) activities as part of the national

¹⁶¹

STH deworming program. In Ethiopia, the study will be conducted in Jimma Zone, Oromia Regional state. In Uganda, the study will be conducted in the district of Central Uganda. The schools will be selected based on previously available data, to ensure sufficient STH cases.

173

3 Processing KK thick smears with our AI-DP (KK2.0)

Processing KK thick smears with the AI-DP (KK2.0) is graphically illustrated in **Fig 1**. To facilitate 175 176 study management, the AI-DP enables EDC for registering study participants (step 1) and 177 provides QR printing spreadsheets and QR label templates. Once the KK thick smears are prepared (with QR code on the slide) (**step 2**), the scanning process is initiated (**step 3**). This 178 179 involves manually loading of the smears into the scanner using a specialized slide holder, after 180 which the QR code is read, and boundary of the stool smear is determined. If required, the 181 user is prompted to manually adjust the scan boundary. In a next step, the slide is 182 automatically scanned, and the scanner captures focus stacks, saving eight images at every field-of-view (FOV) within the KK thick smear (step 3). Following slide scanning, images are 183 transferred to the Slide Manager, and FOVs are analyzed by the AI model for the detection, 184 185 classification, and quantification of helminth eggs (step 4). In a final step, the results 186 generated by the AI undergo review and verification (step 5). This is done through the 187 EggInspector tool, presenting all the AI-determinants from a slide to a trained verifier.

188

Fig 1. An overview of how Kato-Katz (KK) thick smears are processed with the AI-DP (KK2.0).
Al: artificial intelligence, KK: Kato-Katz. Figure created using BioRender.com.

191 **4** The experiments to comprehensively evaluate KK2.0

192 This comprehensive evaluation consists of five experiments, each one designed to evaluate 193 one of the five attributes: (i) diagnostic performance, (ii) repeatability/reproducibility, (iii) 194 time-to-result, (iv) cost-efficiency to inform large-scale deworming programs, and (v) usability 195 in both a laboratory and field setting. **Table 3** provides an overview of the hypotheses, the primary and secondary outcomes for each experiment separately. Across these five 196 197 experiments, we defined 9 hypotheses, 13 primary and 17 secondary outcomes. Generally, 198 we hypothesize that KK2.0 is non-inferior to KK1.0. Note that a hypothesis was not defined for both the time-to-result and usability experiments. This was because the outcomes of the 199 200 time-to-result experiment will feed into the experiment on cost-efficiency and because the 201 usability experiment was designed to gain insights into how we can further improve the 202 usability of KK2.0 only. In the following sections we will discuss each experiment in detail. The 203 sample size calculation and the statistical data analysis will be discussed in sections 2.5. and 204 2.6, respectively.

Experiment	Hypot	theses		Primary outcomes		Secondary outcomes
1) Diagnostic performance	H1.1	the clinical sensitivity of KK2.0 to detect low intensity infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	P1.1 P1.2	the clinical sensitivity of KK2.0 and KK1.0 to detect low intensity infections of <i>Ascaris</i> , <i>Trichuris</i> and hookworms the clinical sensitivity of KK2.0 and KK1.0 to detect MUL infections of Ascaris, <i>Trichuris</i>	S1.1 S1.2	the clinical sensitivity and clinical specificity of KK1.0 and KK2.0 to detect <i>S. mansoni</i> infections the detection limit (the lowest number of eggs that yields a positive test result in 95% of the page) for both KK1.0 and KK2.0 and Access
	H1.2	MHI infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	P1.3	and hookworms the clinical specificity of KK2.0 and KK1.0 to detect any intensity infections of <i>Ascaris</i> ,	S1.3	<i>Trichuris,</i> hookworm, and <i>S. mansoni</i> separately the egg recovery rate of KK1.0 and KK2.0 when compared to the ground truth for <i>Ascaris,</i>
	H1.3	the clinical specificity of KK2.0 to detect any intensity infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	P1.4	<i>Trichuris</i> and hookworms the clinical specificity of KK2.0 and KK1.0 to detect MHI infections of <i>Ascaris, Trichuris</i> and hookworms	S1.4	<i>Trichuris</i> , hookworms and <i>S. mansoni</i> the clinical sensitivity and clinical specificity of the AI-DP when the AI verification process is simplified (limited selection of AI objects
	H1.4	the clinical specificity of KK2.0 to detect MHI infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms				presented for verification) or even omitted
2) Repeatability and re-producibility	H2.1	the repeatability and the reproducibility of the scanning process is at least 99%	P2.1	the repeatability and the reproducibility of the scanning process	S2.1	the agreement between repeated egg counts for Ascaris, Trichuris and S. mansoni
	H2.3	the repeatability and the reproducibility of AI verification process is at least 99% the repeatability and the reproducibility of KK2.0 is at least 99%	P2.2 P2.3	the repeatability and the reproducibility of the AI verification process the repeatability and the reproducibility of the KK2.0	S2.2	the repeatability and reproducibility in test results when the AI verification process is simplified (limited selection of AI objects presented for verification) or even omitted
					S2.3	the repeatability and the reproducibility of KK1.0
3) Time-to-result		We did not define any hypotheses, as the outcomes of this experiment will feed	P3.1	time-to-result for KK2.0	S3.1	time for participant registration using EDC tools and QR printing
		into the experiment on cost-efficiency (section 2.3.4)			S3.2	the correlation between time-to-result and <i>Ascaris, Trichuris</i> and <i>S. mansoni</i> egg counts recorded by KK2.0
					S3.3	time-to-result of the AI-DP when the AI verification process is simplified (limited

Table 3. An overview of the hypotheses, primary, and secondary outcomes to comprehensively evaluate KK2.0.

selection of AI objects presented for verification) or even omitted

4) Cost-efficiency	H4.1 H4.2	the cost-efficiency of KK2.0 to make a reliable program stopping decision is non-inferior to that of KK1.0 the cost-efficiency of KK2.0 to reliably declare that STHs are eliminated as a public health problem is non-inferior to that of KK1.0	P4.1 P4.2	the total survey cost to reliably inform a stop decision the program for KK2.0 and KK1.0 the total survey cost to reliably inform a declaration that STH are eliminated as a public health problem for KK2.0 and KK1.0	S4.1 S4.2 S4.3	the total survey cost to make reliable program decisions on the frequency of large-scale deworming programs for KK2.0 and KK1.0 the total survey cost to reliably monitor the therapeutic drug efficacy of anthelmintic against STHs for KK2.0 the total survey cost to make reliable program decisions on the frequency of large-scale deworming programs for KK2.0 when the AI verification process is simplified (limited selection of AI objects presented for verification)
					S4.4	or even omitted the required performance of AI to make reliable program decisions on the frequency of large-
					S4.5	scale deworming programs for KK2.0 the optimal set-up for KK2.0 (sample throughput; number of AI-DP devices; number of operators) to inform large-scale deworming programs when deployed in a fully equipped laboratory and M&E setting
5) Usability		For this experiment, we did not define any hypotheses	P5.1	ease-of-use/ease-of-learning of (i) the training (ii) the setup, (iii) the scanning, and (iv) the AI verification process for the identified end-users	S5.1	identification of other barriers/facilitators for (i) the training (ii) the setup, (iii) the scanning, and (iv) the AI verification process by the identified end-users
			P5.2	efficiency of (i) the training (ii) the setup, (iii) the scanning, and (iv) the AI verification process for the identified end-users	S5.2	other comparative metrics such as task completion time and rates, error rates, and success rates
			P5.3	satisfaction/low user burden of (i) the training (ii) the setup, (iii) the scanning, and (iv) the AI verification process for the identified end-users		

208 4.1 Diagnostic performance

209 Fig 2 provides an overview of the proposed study design for the experiment on the diagnostic 210 performance. Generally, this experiment consists of five consecutive steps, with the second 211 step offering two methods to validate diagnostic performance. The first method involves 212 verifying egg counts by reviewing and counting all eggs within the captured FOVs. The second method entails spiking a minimum number of eggs into randomly selected stool samples to 213 214 achieve counts indicating an MHI infection. In the first step of the experiment, fresh stool 215 samples will be collected from SAC at the schools. In the second step, the consistency of the 216 stool samples will be scored based on the Bristol Stool Chart [38]. Subsequently, sample will 217 be homogenised, and one KK thick smear per sample will be prepared in one of the two 218 following ways for the two validation methods described above. For FOV-based validation 219 (step 2A), samples will be processed as recommended by WHO. For egg spiking-based 220 validation (step 2B), the cone of stool (after removing the KK template) will be spiked with 221 purified eggs to artificially increase the egg counts to at least an MHI infection (Ascaris: >209 222 eggs; Trichuris: >42 eggs; hookworms: >84 eggs). This step 2B will only be done in a subset of 223 the samples (never on samples that are processed through 2A) and is introduced to ensure 224 that sufficient cases of MHI infections for each of the STHs are obtained (see also section 2.5). 225 The selection of the samples to be spiked will be done through a randomization process. In 226 the **third step** and following a smear clearing time of 30 min, the smears will be randomly 227 allocated to be analysed by either KK1.0 (even participant ID) or KK2.0 (odd participant IDs). 228 This randomization process is required to avoid systematic bias due to hookworm egg 229 degradation over time [13, 14, 39]. In the **fourth step**, egg counts will be recorded for each 230 helminth species (Ascaris, Trichuris, hookworm and S. mansoni), separately. Thereafter (step 231 5), KK thick smears will be stored at 4°C to be used in the context of the experiment on

232 reproducibility/repeatability (see section 2.4.2). In Ethiopia, sample processing (from step 2 233 onwards) will be conducted in the Neglected Tropical Disease Laboratory of Jimma University 234 (a fully equipped laboratory setting), while in Uganda all steps will be conducted on-site (M&E 235 setting). 236 237 Fig 2. Overview of the study design for the experiment on diagnostic performance. FOV: 238 field-of-view, KK: Kato-Katz. Figure created using BioRender.com. 239 240 In absence of a gold standard, it will be important to define the ground truth for each slide 241 separately, to test the hypotheses (H1.1 – H.1.4). For the slides that were not spiked, all FOVs 242 that were captured through the AI-DP will be manually annotated by one trained laboratory 243 technician. A second trained laboratory technician will then verify the annotations. In case of

samples, the ground truth (samples being classified as MHI infection) is already established 245 through the process of spiking.

disagreement, a third trained laboratory technician will make the final call. For the spiked

247

246

244

4.2 **Repeatability and reproducibility** 248

249 In this experiment, we will be evaluating the two parameters repeatability and 250 reproducibility. Repeatability refers to the variability in test results (Ascaris, Trichuris and S. 251 mansoni) when the same KK thick smear is examined by the same operator (e.g. scanner of 252 AI-DP/microscopist), so called intra-annotator agreement, while reproducibility refers to the 253 variability in test results when the same slide is examined by a different operator (e.g. scanner 254 of AI-DP/microscopist), so called inter-annotator agreement (see also Fig 3 for graphic 255 definition of both repeatability and reproducibility). For KK2.0, we will focus on the scanning

process (step 3 in **Fig 1**) and the AI verification process (step 5 in **Fig 1**). For KK1.0, we will focus on the egg counting process only (see also **Fig 3**). Generally, we hypothesise that both the repeatability and reproducibility of KK2.0 is at least 99%.

259 Fig 3 provides an overview of the proposed study design for the experiment on the 260 repeatability and reproducibility. For this experiment, we will use a subset of the KK thick 261 smears prepared during the experiment on the diagnostic performance. The subset will 262 comprise two slide boxes, each containing 45 KK thick smears. To ensure we assess the 263 repeatability and reproducibility across different egg counts, we will randomly select 30 264 negative KK thick smears, 30 smears with a total egg count for any helminths (Ascaris, Trichuris and S. mansoni) between 1 and 100, and 30 smears with a total egg count greater 265 266 than 100, resulting in a total of 90 smears. We will ensure that at least 50% of the KK thick 267 smears in each box contain eggs from at least two different helminth species.

268 For the repeatability and reproducibility of the scanning process (KK2.0), all KK thick smears 269 in slide box #1 (green) and box #2 (blue) will undergo two rounds of scanning. To ensure the 270 entire sample is scanned, boundaries will be set larger than the smear for every scan, limiting 271 interference and error caused by human error. The repeatability and reproducibility of the 272 scanner process will be based on the final test results generated by the complete scanning 273 process, which includes slide loading, boundary setting, device calibration, automatic focus 274 setting, scan algorithms, AI detections and egg grouping algorithms. For the repeatability and 275 reproducibility of the result verification process, the AI results of the unique scans of scanner 276 #1 (red frame) will be verified by at least two different microscopists. For KK1.0, the 277 examination of the KK thick smears will be conducted using the same flow as applied for the 278 Al verification process. We will ensure that the same microscopists examine the same slides 279 for both KK1.0 and do the AI verification for KK2.0.

- 281 Fig 3. Overview of the study design for the experiment on the repeatability and
- 282 reproducibility. Figure created using BioRender.com.

283 4.3 Time-to-result

284 During the experiments on the diagnostic performance (section 2.4.1), and repeatability and reproducibility (section 2.4.2), four different steps of the KK2.0 procedure will be timed. The 285 286 four steps involve (i) participant registration (step 1 in Fig 1), (ii) the scanning process (step 3 287 in Fig 1), (iii) the AI process (step 4 in Fig 1), and (iv) the verification process (step 5 in Fig 1). 288 The time required for each of these steps to be completed will be recorded by the AI-DP. The 289 total time-to-result will be defined as the sum of the durations needed for the individual steps. 290 Furthermore, in the Ugandan field setting, the time for setting up the AI-DP system at the 291 different field locations will be recorded. The time-to-result for KK1.0 will not be measured in 292 the present study. This has been intensively researched elsewhere as part of four clinical 293 trials, each trial conducted in a different country [29, 40]. We will use these data as a 294 comparator for KK2.0.

295

296 4.4 Cost-efficiency

297 For this experiment, we built up on two general frameworks that were previously developed 298 to support cost-efficient study design choices for large-scale STH deworming programs, 299 including epidemiological surveys to reduce/stop large-scale deworming programs and to 300 declare STH eliminated as a public health problem [41, 42], and to monitor the therapeutic 301 drug efficacy [22]. Generally, these frameworks consist of three consecutive steps. In the **first** 302 step, an in-depth analysis of the operational costs to process one stool sample is conducted 303 for each diagnostic tool. In the second step, simulation studies are performed to determine 304 the probability of making the reliable program decision. In the **third step**, the outcome of the 305 cost assessment is integrated into the simulation study to estimate the total survey costs and 306 determined the most cost-efficient study design. For the in-depth analysis of the operational

307 costs to process one sample, we will both conduct an itemized cost assessment and 308 determine the salary costs, which will be a function of the time-to-result (see section 2.4.3). 309 For the simulation, we will deploy simulation frameworks previously published by both 310 Kazienga et al. (2023) and Coffeng et al. (2023) [22, 41]. Both frameworks account for different 311 sources of variation in egg counts, including (i) variability in mean egg intensity between 312 schools; (ii) inter-individual variability in mean egg intensity due to variation in infection levels 313 between individuals, where the level of aggregation is a linear function of the school-level 314 mean egg intensity; (iii) day-to-day variability in mean egg intensity within an individual due 315 to heterogeneous egg excretion over time; (iv) variability in egg counts between repeated 316 aliquots of a stool sample due to the aggregated distribution of eggs in stool; (v) inter-317 individual variability in the effect of drug administration. Through the outputs of the 318 experiment on both the diagnostic performance (section 2.4.1), and the repeatability and 319 reproducibility (section 2.4.2), we will be able to further customize the simulation work to 320 KK2.0 (e.g., additional variation in test results due to AI verification process and imperfect egg 321 recovery).

323 **4.5 Usability**

We define usability as the degree to which the KK2.0 can be used easily, efficiently, and with satisfaction/low user burden by the stakeholders [43]. For this experiment, KK2.0 naïve participants (having no previous exposure or experience with the system) will receive practical training in the use of the KK2.0 system, which includes three steps, namely the setup, the scanning, and the AI verification process.

329 The practical training consists of an initial demonstration of this three-step process and a 330 walk-through of system user manuals. Afterwards, the participants will be invited to two 331 natural use environments, either to a laboratory setting, or a field setting. The participants 332 will be organized into four groups per setting, each consisting of two participants per group, 333 resulting in a total of 16 participants. This grouping reflects a planned real-life group setup, wherein the involvement of two laboratory technicians are expected to carry out the tasks. 334 335 The group will be asked to perform the set-up as a team. The two following steps, the scanning 336 and verifying AI, will be performed individually. For this, participants will be asked to each 337 process 6 slides with KK2.0. Each slide will be processed in following order, whereby the 338 participant's effort will be increased: (1) the final results are available soon after scanning is 339 complete (e.g., KK2.2 results), (2) the user must perform the simple verification procedure 340 before the results are available, (3) the user must perform the complete verification 341 procedure before the results are available. During the three-step task performance, 342 participants will verbalize their experiences and detect weak points in their interaction with 343 the scanner (i.e., think-aloud protocol [44]). The whole session will be video-recorded, and 344 data will be generated by verbatim transcriptions, and an observation checklist for collecting 345 comparative metrics (e.g., task completion time and both error and success rates). Following, 346 a semi-structured interview will be implemented to capture the ease-of-use/ease-of-learning,

efficiency, and satisfaction/low user burden, as well as potentially missed barriers and facilitators during the task completion process. The interviews will be conducted by one investigator and structured around four sections: the background of the participant; the training; the KK2.0; the context. The data will be audio-recorded and transcribed verbatim.

351

352 **5** Sample size calculation

A formal sample size calculation was conducted for the experiments on the diagnostic 353 354 performance (section 2.4.1), and the repeatability and reproducibility (section 2.4.2). For the other experiments we did not determine the sample size, because either no hypothesis was 355 defined as the outcomes will feed into another experiment (section 2.4.3 Time-to-result), the 356 357 hypothesis is based on a simulation study (section 2.4.4 Cost efficiency), or the sample size 358 was based on common practice in literature (2.4.5. Usability). In the following sections we 359 will only briefly discuss the applied methodology to determine the sample size for the three experiments (diagnostic performance, repeatability/reproducibility, and usability). For a 360 detailed description of the applied methodology for the first two experiments we refer the 361 362 reader to S1 Info.

363

5.1 Diagnostic performance, repeatability, and reproducibility

Generally, we opted to conduct a series of simulation studies over the standard sample size methodologies, as this approach allowed us (i) to better capture the variation in test results that are otherwise difficult to account for (e.g., clinical sensitivity of KK1.0 increases as a function of egg numbers in a slide), and (ii) to ensure that the sample size calculation and the final interpretation of the field data are both based on the same statistical approach (e.g., the

relative position of confidence intervals (CI) to predefined set of values; see also **Fig 4**). In brief, each of these simulation studies consists of a series of in-silico experiments that are iterated under different conditions (e.g., different sample sizes). Based on this iterative process, we determined the lowest sample size that allowed for confirming the hypothesis in at least 80% of the iterations (= power).

375

Fig 4. Overview of the different outcome scenarios based on a random sample and its corresponding CI. This figure illustrates the different outcome scenarios around the difference in performance between KK2.0 and KK1.0 based on the CI. The green lines represent the scenarios where there is evidence of non-inferiority, while the lines in orange illustrate the scenarios where there is no evidence of non-inferiority. In this example we set the level of equivalence at -5 percent difference between (KK2.0 – KK1.0), a negative value indicating that KK1.0 is better.

383

384 5.1.1 Diagnostic performance

385 For the clinical sensitivity to detect low intensity (H1.1) and MHI infections (H1.2), we 386 accounted for (i) a varying clinical sensitivity as a function of the number of eggs in a slide; (ii) 387 a proportion of the eggs in a slide being missed, (iii) correlation between test results of KK1.0 388 and KK2.0 on the same slide, (iii) and helminth specific FEC thresholds defining low intensity 389 and MHI infections (Table 4). In this simulation, we assumed that the clinical sensitivity of 390 KK2.0 is equal to that of KK1.0 and an equivalence level of 5-point percent. In other words, 391 the lower limit of the CI around the difference (KK2.0 – KK1.0) should be at least -5% (see also 392 Fig 4). As we will draw conclusions on three different STHs at the same time and because we 393 are testing for non-inferiority, we set the level of significance at 0.05/3.

394

395 Table 4. The FEC thresholds defining low intensity and MHI STH infections. This table 396 summarizes the WHO FEC (in EPG) thresholds to classify the intensity of STH infections into low, moderate and heavy [45]. 397

Helminth	Low	Moderate	Heavy
Ascaris	1 – 4,999	5,000 – 49,999	≥50,000
Trichuris	1 – 999	1,000 – 9,999	≥10,000
Hookworm	1 – 1,999	2,000 – 3,999	≥4,000

398

399 Based on these assumptions, the required number of KK thick smears representing low 400 intensity infections based on the ground truth is 125 for Ascaris, 180 for Trichuris and 140 for 401 hookworms. The required number of KK thick smears representing MHI infections based on the ground truth, is 110 for Ascaris and 145 for Trichuris. For hookworms, the required sample 402 403 size exceeded 350, which revealed to be beyond the capacity of this project.

404 For the clinical specificity to detect any intensity (H1.3) and MHI infections (H1.4), we used 405 another data generation process (based on binary test results (positive/negative) instead of egg counts). Because of this, the required sample size is the same for each of the different 406 407 STHs. In this simulation study, we also (i) accounted for correlation between test results of 408 KK1.0 and KK2.0 on the same KK thick smear, (ii) assumed an equal clinical specificity for both 409 diagnostic tools, an equivalence level of 5-point percent, and (iii) set the level of significance 410 at 0.05/3. Based on these assumptions, the required number of KK thick smears representing 411 no infections based on the ground truth is 225 for Ascaris, Trichuris and hookworms each. 412 Consequently, the required number of KK thick smears representing low intensity infections based on the ground truth is also 165 for each of the three STHs separately. 413

414

415 5.1.2 Repeatability and reproducibility

416 To verify whether the repeatability and reproducibility for the scanner set-up (H2.1), the AI 417 verification process (H2.2), and the complete KK2.0 (H2.3), is at least 99%, we conducted a 418 simulation study where we determined the number of KK thick smears that resulted in a lower 419 limit of the CI that is at least 95% in 80% (= power) of the iterations when the true underlying 420 probability of success equals 99%. Given that we are testing both repeatability and 421 reproducibility at same time for each process, and that we are testing for non-inferiority, we set the level of significance at 0.05/2. Based on these assumptions the, required KK thick 422 423 smears that need to be re-processed equals 90 for each of the three hypotheses.

424

425 **5.2 Usability**

In this experiment, we will include 16 participants to receive (i) practical training and engage in the three-step process (ii – iv) and usability testing. A group size of 3-20 participants is considered valid in such problem discovery scenarios, with 5-10 participants being a sensible baseline range [46]. The group size should typically be increased along with the study's complexity and the criticality of its context. Since the study will take place in two different settings, either in a well-equipped laboratory or field setting, we considered 8 participants per setting, resulting in a total of 16 participants (4 groups of 2 participants per setting).

433 Table 5. Overview of the required number of KK thick smear to test the hypotheses for the experiments on diagnostic performance and repeatability/reproducibility.

Experiment	Hypothesis	Intensity of infection	Number of KK thick smear			
			Any STH	Ascaris	Trichuris	Hookworm
Diagnostic p	erformance					
	H1.1: the clinical sensitivity of KK2.0 to detect low intensity infections is non-inferior to that of KK1.0 for Ascaris, Trichuris and bookworms	Low	-	125	180	140
	H1.2: the clinical sensitivity of KK2.0 to detect MHI infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	MHI	-	110	145	>350
	<i>H1.3</i> : the clinical specificity of KK2.0 to detect any intensity infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	No infection	-	225	225	225
	H1.4: the clinical specificity of KK2.0 to detect MHI infections is non-inferior to that of KK1.0 for <i>Ascaris, Trichuris</i> and hookworms	Low	-	165	165	165
Repeatability	v and reproducibility					
	H2.1: the repeatability and the reproducibility of the scanner set-up process is at least 99%	All	90	-	_	_
	H2.2: the repeatability and the reproducibility of AI verification process is at least 99%	All	90	-	_	_
	H2.3: the repeatability and the reproducibility of KK2.0 is at least 99%	All	90			

436 6 Statistical data analysis

437 6.1 Diagnostic performance

438 6.1.1 Primary outcomes

439 We will draw contingency tables representing the test results of both KK1.0 and KK2.0 for 440 each type of ground truth (no, low intensity and MHI infections) and STH species (Ascaris, 441 Trichuris and hookworms). From these tables, both the clinical sensitivity and specificity, and the corresponding 95% CI (Wald) will be calculated for each test and STH separately. 442 443 Subsequently, we will also calculate the 90% CI around the difference in performance (KK2.0-444 KK1.0). Given that test results are paired (same smears are processed by KK1.0 and KK2.0, we 445 will use the formulae described by Newcombe for paired data [47]. We will conclude that the clinical sensitivity or specificity of KK2.0 for a particular STH is non-inferior if the lower limit 446 447 of the 90% CI does not include the -5-point percent.

448

449 6.1.2 Secondary outcomes

We will draw contingency tables representing the test results of both KK1.0 and KK2.0 for each type of ground truth for *S. mansoni* infections. From these tables, both the clinical sensitivity and specificity, and the corresponding 95% CI will be calculated (*S1.1*).

To determine the detection limit (the lowest number of eggs that yields a positive test result in 95% of the cases) of KK1.0 and KK2.0 for STH and *S. mansoni* (**S1.2**), logistic regression models accounting for repeated measures will be built for each helminth species separately using the 'mixed_model' function in R. The test result (positive or negative) will be used as dependent variable while 'test' (2 levels: 'KK1.0', 'KK2.0'), log transformed egg counts based on ground truth at first examination, Bristol stool scale and all two-way interactions will be

459 used as predicting variables. From these models, we will predict the probability having a 460 positive test result and the corresponding 95% prediction interval for each integer value of 461 ground truth egg counts between 1 and 100 using the 'marginal' coefs' function in R. We will 462 define the detection limit as that range of egg counts for which the 95% prediction intervals 463 include 0.95. We will explore the egg recovery rate (= observed egg counts / ground truth egg 464 counts) of KK1.0 and KK2.0 when compared to the ground truth for Ascaris, Trichuris, 465 hookworms and S. mansoni (S1.3). These analyses will only be conducted on KK thick smears 466 representing low intensity infections. Finally, we will draw contingency tables representing 467 the test results of KK2.0 for each type of ground truth (negative, low intensity and MHI infections) for each helminth species and AI verification process (simplified AI verification 468 469 (limited selection of AI objects presented for verification) vs. no AI verification), separately. 470 From these tables, both the clinical sensitivity and specificity, and the corresponding 95% CI 471 will be calculated for each helminth species and type of AI-verification process (S1.4).

472

473 6.2 Repeatability and reproducibility

474 6.2.1 Primary outcomes

The egg counts on the same smear will be considered not repeatable/reproducible in one of the following three scenarios of discrepancy: (i) there is a difference in presence/absence, (ii) the difference in egg counts exceeds 10 eggs for slides with egg counts ≤100 eggs, (ii) the difference in egg counts exceeds 20% eggs for slides with egg counts >100 eggs. These criteria are developed by the Swiss Tropical Institute of Tropical and Public Health (Speich et al., 2015), and are currently the standard way of quality control of egg counts in clinical trials [25, 26].

To determine the repeatability (proportion of cases for which a repeated test result by the 482 483 same operator/scan met the aforementioned criteria) and reproducibility (proportion of 484 cases for which a repeated test result by a different operator/scan met the aforementioned 485 criteria) of the scanning process (P2.1) and Al-verification (P2.2), we will draw contingency 486 tables representing the repeated test results of KK2.0 on the same KK thick smears by the 487 same operator / scanner (repeatability) or different operator / scanner (reproducibility) for each of the different steps of the KK2.0. From these tables, both the repeatability and 488 489 reproducibility, and the corresponding 90% CI (Wald) will be calculated for the scanning 490 process, AI-verification and complete KK2.0, separately. We will conclude that the 491 reproducibility/repeatability of these steps are at least 99% if the 90% CI does not include 95%. 492

493

494 6.2.2 Secondary outcomes

We will explore the agreement in repeated egg counts by using a Bland-Altmann plot for the scanning process, AI-verification, the complete KK2.0 and KK1.0 for each of the three helminths, separately (*S2.1*). In addition, we will repeat the analysis of repeatability and reproducibility for both a simplified AI-result verification process (limited selection of AI objects presented for verification) and where AI-result verification is omitted (*S2.2*).

500

501 6.3 Time-to-result

We will determine the mean (and corresponding 95% confidence intervals) time-to-result (*P3.1*) and the time for participant registration using EDC tools (*S3.1*). In addition, we will also explore the correlation between time-to-result and *Ascaris, Trichuris* and *S. mansoni* egg counts recorded by KK2.0 (*S3.2*) based on the Spearman's coefficient. Finally, we will repeat

506	the analysis to determine the time-to-result of our AI-DP when the AI verification process is
507	simplified (limited selection of AI objects presented for verification) and where AI-result
508	verification is omitted (<i>S3.3.</i>)

509

510 6.4 Cost-efficiency

511 We refer the reader to **section** 2.4.4.2 for more details.

512

513 **6.5 Usability**

514 To achieve a thorough comprehension of the training and scanner usability, we will employ 515 data triangulation as a method for analysing and incorporating multiple data sources. The 516 approach to gualitative data analysis will combine inductive and deductive elements, using the determinants of usability: ease-of-use; efficiency; satisfaction/low user burden. Analytical 517 518 categories will be developed from the initial research questions and emerge during the 519 analysis process. Using NVivo (Version 14, 2020, Lumivero), identified categories will be 520 operationalized as codes in a flexible coding scheme. The content of the codes will be 521 discussed extensively between independent coders, and subsequently used to identify pain 522 points and to explore improvements. The quantitative data obtained through the observational checklists will be analyzed through basic descriptive statistics. 523

524

525 **Discussion**

526 Despite the well-known limitations of KK thick smear, it is probably here to stay for the next 527 decade. As response to this, we have designed and developed an AI-DP (KK2.0) that could 528 overcome some of these limitations. Moreover, by incorporating both EDC tools and cloudbased reporting with a monitoring dashboard that can be integrated into existing health systems, KK2.0 holds promise as an end-to-end diagnostic tool in large-scale deworming programs targeting STH. Encouraged by preliminary results on the diagnostic performance, we now want to provide the data necessary to make more evidence-based decisions on the potential of this AI-DP.

534

1 Comprehensive evaluation beyond diagnostic performance

536 While the evaluation of new diagnostic methods has often been limited to the clinical sensitivity and specificity only, we deliberately opted to evaluate additional attributes and 537 combine them into a simulation study that is designed to determine the cost-efficiency of the 538 539 AI-DP to inform large-scale deworming programs. As recently illustrated for monitoring the 540 therapeutic efficacy against STHs [22], we strongly believe that this holistic approach is 541 required to make any evidence and value-based decisions. This is particularly relevant for STH control programs which operate in resource poor settings, and hence it will be important to 542 543 ensure reliable and confident programmatic decision making, while minimizing the 544 operational costs. Moreover, a complex interplay exists between the diagnostic performance 545 and the epidemiological setting (e.g., clinical sensitivity reduces in low endemic setting [15, 546 41], the sample throughput, and the operational costs (e.g., improving the diagnostic 547 performance and the corresponding reduced sample sizes can compensate for more costly 548 tests and lower sample throughput; there is a limit to the extent to which higher reagent costs 549 can be compensated by lower sample throughput) [23, 42]. In other words, it would be quite 550 impossible to draw conclusions on whether any new diagnostic method holds promise to 551 inform large-scale deworming programs without fully exploring these aspects in more detail

552 [22, 41]. On top of these, we have set-up a usability experiment, to further adjust the AI-DP553 to user's requirements.

554

555 2 Estimates of diagnostic performance are not absolute, but

relative to KK1.0

For many infectious diseases, the absence of a gold standard (100% sensitivity and specificity) 557 558 is a universal challenge to estimate the true performance of new diagnostics [48, 49]. To 559 overcome this obstacle for STHs, it has been suggested to examine more stool samples with 560 multiple diagnostic methods [50-53], and to deploy statistical methodologies that account for 561 the absence of a gold standard [49]. In our study, we will determine the diagnostic performance of the AI-DP relative to the current diagnostic standard (KK1.0). In our opinion 562 563 choosing KK1.0 as a sole comparator is justified. First, the AI-DP aims to improve the current KK1.0, and hence it is the obvious comparator to test the non-inferiority hypotheses. Second, 564 565 for MHI infections, KK1.0 remains the sole diagnostic method to define the intensity of 566 infections [23, 24]. Third, it has recently been shown that the clinical specificity, rather than 567 the clinical sensitivity, will become more important when programs progress towards control 568 and elimination of STH [23, 54]. Clinical specificity of KK1.0 thick smear (95% [16, 25, 26]) has 569 never been considered as a drawback, which takes away the need for a more sensitive comparator (e.g., qPCR [15, 55]). Finally, we carefully designed the experiments so that we 570 571 can ensure the true underlying infection status. For the KK smears representing no infections 572 or infections of low intensity, we will have the ground truth based on the scans of the KK thick smears, while for the smears representing MHI infections we will spike the slides with known 573 number of eggs. This design allows us to draw the appropriate conclusions around the defined 574

575 non-inferiority hypotheses without the need of other diagnostic methods (e.g., qPCR) or more
576 complex statistical models that account for a gold standard.

577

3 Alignment with WHO TPPs for STHs

579 In 2021, WHO published its TPP for STH, defining the minimal and ideal criteria for 38 580 attributes organized in five clusters (product use summary: 5 attributes; design: 11 attributes; performance: 10 attributes; product configuration: 5 attributes; product cost and channels: 5 581 582 attributes)[24]. A year later, we systematically analysed this TPP for an AI-DP solution [27]. **Fig 5** provides a graphical overview per cluster of how the current AI-DP already meets these 583 584 criteria, and for which attributes this study will provide full, partial or no evidence. In S2 Info, 585 we provide the same information for each attribute separately. Today, our AI-DP already 586 meets 14 attributes and through this study we will provide partial or full evidence for another 587 17 attributes. The study will not address the remaining 7 attributes because they are considered to be out of scope. Most of these attributes are within product configuration 588 589 (shipping conditions and labelling and instructions for use), and product cost and channels 590 (product lead times, target launch countries and product registration), and therefore will 591 need to be addressed at a later stage when there is sufficient evidence that our AI-DP meets 592 the other attributes. Note that, the reproducibility and repeatability is not considered as an 593 attribute in the WHO TPP.

594

Fig 5. Overview per cluster of how the current AI-DP already meets the attributes defined
in the WHO TPP criteria, and for which attributes this study will provide full, partial or no
evidence.

598

599 4 Moving from KK2.0 over KK2.1 to K2.2

600	Today, the AI-DP still relies on the human operator to verify all the detections by AI (KK2.0).
601	It is our ambition to further minimize this in two consecutive steps. In first step, we will reduce
602	the number of detections presented for human verification, e.g., to the detections for which
603	there is doubt (KK2.1). In a final step, all human verification will be removed, and results will
604	rely on AI only (KK2.2). During this study, we will already gather the evidence for both KK2.1
605	and KK2.2 (secondary outcomes S1.5, S2.2, S3.3, S4.3; see Table 3). Moreover, through the
606	usability experiment we will be able to further customize the AI-DP and corresponding needs
607	of the key end-users.

608

609 **Conclusions**

This comprehensive study will provide the necessary data to make an evidence-based decision on whether our AI-DP is indeed a cost-efficient end-to-end diagnostic to inform largescale deworming programs against STHs. In case of a favourable outcome, we will seek further guidance by WHO. Meanwhile, we provide full access to sample size calculations and record forms, which may be relevant for the evaluation of any other AI-DP or diagnostic.

615 **References**

Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, et al. Soil transmitted helminth infections: ascariasis, trichuriasis, and hookworm. The Lancet.
 2006;367(9521):1521-32. doi: 10.1016/s0140-6736(06)68653-4.

Hotez PJ, Bundy DA, Beegle K, Brooker S, Drake L, de Silva N, et al. Helminth infections:
soil-transmitted helminth infections and schistosomiasis. In: Disease Control Priorities in
Developing Countries. 2nd edition. Washington (DC): The International Bank for
Reconstruction and Development / The World Bank; 2006. Chapter 24.

3. World Health Organization. Preventive chemotherapy and Transmission Control
Database; https://www.who.int/data/preventive-chemotherapy; accessed on July 1, 2023.

625 4. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019:

a systematic analysis for the Global Burden of Disease Study 2019. Lancet.
2020;396(10258):1204-22. Epub 2020/10/19. doi: 10.1016/s0140-6736(20)30925-9. PubMed
PMID: 33069326; PubMed Central PMCID: PMCPMC7567026.

629 5. World Health Organization. Soil-transmitted helminth infections [Internet];
630 https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections;

631 accessed on September 23 2023.

632 6. World Health Organization. Helminth control in school-age children: a guide for
633 managers of control programmes. 2nd ed. 2011. ISBN: 9789241548267

634 7. World Health Organization. 2030 targets for soil-transmitted helminthiases control
635 programmes. Geneva. 2019. Licence: CC BY-NC-SA 3.0 IGO.

8. World Health Organization. Schistosomiasis and soil-transmitted helminthiases:
progress report, 2021. Weekly epidemiological record. 2022;97(48):621-632.

9. Sartorius B, Cano J, Simpson H, Tusting LS, Marczak LB, Miller-Petrie MK, et al.
Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan
Africa, 2000-18: a geospatial analysis. Lancet Glob Health. 2021;9(1):e52-e60. Epub
2020/12/19. doi: 10.1016/s2214-109x(20)30398-3. PubMed PMID: 33338459; PubMed
Central PMCID: PMCPMC7786448.

Bradley M, Taylor R, Jacobson J, Guex M, Hopkins A, Jensen J, et al. Medicine donation 643 10. programmes supporting the global drive to end the burden of neglected tropical diseases. 644 645 Trans R Soc Trop Med Hyg. 2021;115(2):136-44. Epub 2021/01/17. doi: 10.1093/trstmh/traa167. 646 PubMed PMID: 33452881; PubMed Central PMCID: PMCPMC7842096. 647

World Health Organization. Ending the neglect to attain the Sustainable Development
Goals: a road map for neglected tropical diseases 2021–2030. Geneva; 2020. Licence: CC BYNC-SA 3.0 IGO.

Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear
technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972;14(6):397-400.
Epub 1972/11/01. PubMed PMID: 4675644.

World Health Organization. Bench aids for the diagnosis of intestinal parasites, second
edition. Geneva. 2019. Licence: CC BY-NC-SA 3.0 IGO.

Dacombe RJ, Crampin AC, Floyd S, Randall A, Ndhlovu R, Bickle Q, et al. Time delays
between patient and laboratory selectively affect accuracy of helminth diagnosis. T Roy Soc
Trop Med H. 2007;101(2):140-5. doi: https://doi.org/10.1016/j.trstmh.2006.04.008.

Cools P, Vlaminck J, Albonico M, Ame S, Ayana M, José Antonio BP, et al. Diagnostic
performance of a single and duplicate Kato-Katz, Mini-FLOTAC, FECPAKG2 and qPCR for the

detection and quantification of soil-transmitted helminths in three endemic countries. Plos
Neglect Trop D. 2019;13(8):e0007446. doi: 10.1371/journal.pntd.0007446.

16. Nikolay B, Brooker SJ, Pullan RL. Sensitivity of diagnostic tests for human soiltransmitted helminth infections: a meta-analysis in the absence of a true gold standard. Int J
Parasitol. 2014;44(11):765-74. Epub 2014/07/06. doi: 10.1016/j.ijpara.2014.05.009. PubMed
PMID: 24992655; PubMed Central PMCID: PMCPMC4186778.

Moser W, Barenbold O, Mirams GJ, Cools P, Vlaminck J, Ali SM, et al. Diagnostic
comparison between FECPAKG2 and the Kato-Katz method for analyzing soil-transmitted
helminth eggs in stool. PLoS Negl Trop Dis. 2018;12(6):e0006562. Epub 2018/06/05. doi:
10.1371/journal.pntd.0006562. PubMed PMID: 29864132; PubMed Central PMCID:
PMCPMC6002127.

672 18. Cringoli G, Maurelli MP, Levecke B, Bosco A, Vercruysse J, Utzinger J, et al. The Mini673 FLOTAC technique for the diagnosis of helminth and protozoan infections in humans and
674 animals. Nature Protocols. 2017;12(9):1723-32. doi: 10.1038/nprot.2017.067.

Cringoli G, Rinaldi L, Maurelli MP, Utzinger J. FLOTAC: new multivalent techniques for
qualitative and quantitative copromicroscopic diagnosis of parasites in animals and humans.
Nat Protoc. 2010;5(3):503-15. Epub 2010/03/06. doi: 10.1038/nprot.2009.235. PubMed
PMID: 20203667.

Ayana M, Vlaminck J, Cools P, Ame S, Albonico M, Dana D, et al. Modification and
optimization of the FECPAKG2 protocol for the detection and quantification of soiltransmitted helminth eggs in human stool. PLoS Negl Trop Dis. 2018;12(10):e0006655. Epub
2018/10/16. doi: 10.1371/journal.pntd.0006655. PubMed PMID: 30321180; PubMed Central
PMCID: PMCPMC6224113.

O'Connell EM, Nutman TB. Molecular Diagnostics for Soil-Transmitted Helminths. The
American journal of tropical medicine and hygiene. 2016;95(3):508-13. Epub 2016/08/01. doi:
10.4269/ajtmh.16-0266. PubMed PMID: 27481053.

687 22. Coffeng LE, Vlaminck J, Cools P, Denwood M, Albonico M, Ame SM, et al. A general 688 framework to support cost-efficient fecal egg count methods and study design choices for 689 large-scale STH deworming programs-monitoring of therapeutic drug efficacy as a case study. 690 PLoS 2023;17(5):e0011071. Negl Trop Dis. Epub 2023/05/17. doi: 691 10.1371/journal.pntd.0011071. PubMed PMID: 37196017; PubMed Central PMCID: 692 PMCPMC10228800.

Levecke B, Coffeng LE, Hanna C, Pullan RL, Gass KM. Assessment of the required
performance and the development of corresponding program decision rules for neglected
tropical diseases diagnostic tests: Monitoring and evaluation of soil-transmitted helminthiasis
control programs as a case study. PLoS Negl Trop Dis. 2021;15(9):e0009740. Epub
2021/09/15. doi: 10.1371/journal.pntd.0009740. PubMed PMID: 34520474; PubMed Central
PMCID: PMCPMC8480900.

World Health Organization. Diagnostic target product profiles for monitoring and
evaluation of soil-trans- mitted helminth control programs. 2021. Licence: CC BY-NC-SA 3.0
IGO.

Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Dana D, et al. An in-depth report of
quality control on Kato-Katz and data entry in four clinical trials evaluating the efficacy of
albendazole against soil-transmitted helminth infections. PLoS Negl Trop Dis.
2020;14(9):e0008625. Epub 2020/09/22. doi: 10.1371/journal.pntd.0008625. PubMed PMID:
32956390; PubMed Central PMCID: PMCPMC7549791.

26. Speich B, Ali SM, Ame SM, Albonico M, Utzinger J, Keiser J. Quality control in the
diagnosis of Trichuris trichiura and Ascaris lumbricoides using the Kato-Katz technique:
experience from three randomised controlled trials. Parasit Vectors. 2015;8:82. Epub
2015/02/06. doi: 10.1186/s13071-015-0702-z. PubMed PMID: 25652120; PubMed Central
PMCID: PMCPMC4326492.

Ward P, Dahlberg P, Lagatie O, Larsson J, Tynong A, Vlaminck J, et al. Affordable
artificial intelligence-based digital pathology for neglected tropical diseases: A proof-ofconcept for the detection of soil-transmitted helminths and Schistosoma mansoni eggs in
Kato-Katz stool thick smears. Plos Neglect Trop D. 2022;16(6):e0010500. doi:
10.1371/journal.pntd.0010500.

Stuyver LJ, Levecke B. The role of diagnostic technologies to measure progress toward
WHO 2030 targets for soil-transmitted helminth control programs. PLoS Negl Trop Dis.
2021;15(6):e0009422. Epub 2021/06/04. doi: 10.1371/journal.pntd.0009422. PubMed PMID:
34081694.

721 Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Bethony J, et al. Comprehensive 29. 722 evaluation of stool-based diagnostic methods and benzimidazole resistance markers to assess drug efficacy and detect the emergence of anthelmintic resistance: A Starworms study 723 724 protocol. PLoS Negl Dis. 2018;12(11):e0006912. Epub 2018/11/06. Trop doi: 725 10.1371/journal.pntd.0006912. PubMed PMID: 30388108; PubMed Central PMCID: PMCPMC6235403. 726

30. Dana D, Roose S, Vlaminck J, Ayana M, Mekonnen Z, Geldhof P, et al. Longitudinal
assessment of the exposure to Ascaris lumbricoides through copromicroscopy and serology
in school children from Jimma Town, Ethiopia. PLoS Negl Trop Dis. 2022;16(1):e0010131.
Epub 2022/01/19. doi: 10.1371/journal.pntd.0010131. PubMed PMID: 35041666.

Tadege B, Mekonnen Z, Dana D, Sharew B, Dereje E, Loha E, et al. Assessment of
environmental contamination with soil-transmitted helminths life stages at school
compounds, households and open markets in Jimma Town, Ethiopia. PLoS Negl Trop Dis.
2022;16(4):e0010307. Epub 2022/04/05. doi: 10.1371/journal.pntd.0010307. PubMed PMID:
35377880; PubMed Central PMCID: PMCPMC9009776.

736 32. Tadege B, Mekonnen Z, Dana D, Tiruneh A, Sharew B, Dereje E, et al. Assessment of 737 the nail contamination with soil-transmitted helminths in schoolchildren in Jimma Town, 738 Ethiopia. PLoS One. 2022;17(6):e0268792. Epub 2022/06/30. doi: 739 10.1371/journal.pone.0268792. PubMed PMID: 35767573; PubMed Central PMCID: 740 PMCPMC9242460.

741 33. Ayana M, Cools P, Mekonnen Z, Biruksew A, Dana D, Rashwan N, et al. Comparison of 742 four DNA extraction and three preservation protocols for the molecular detection and 743 quantification of soil-transmitted helminths in stool. PLoS Negl Trop Dis. 2019;13(10):e0007778. Epub 2019/10/29. doi: 10.1371/journal.pntd.0007778. PubMed 744 745 PMID: 31658264; PubMed Central PMCID: PMCPMC6837582.

Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Cringoli G, et al. Therapeutic efficacy
of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic
methods. Plos Neglect Trop D. 2019;13(8):e0007471. doi: 10.1371/journal.pntd.0007471.

35. Dana D, Mekonnen Z, Emana D, Ayana M, Getachew M, Workneh N, et al. Prevalence
and intensity of soil-transmitted helminth infections among pre-school age children in 12
kindergartens in Jimma Town, southwest Ethiopia. Trans R Soc Trop Med Hyg.
2015;109(3):225-7. Epub 2014/11/06. doi: 10.1093/trstmh/tru178. PubMed PMID:
25371496.

36. Mekonnen Z, Meka S, Ayana M, Bogers J, Vercruysse J, Levecke B. Comparison of Individual and Pooled Stool Samples for the Assessment of Soil-Transmitted Helminth Infection Intensity and Drug Efficacy. Plos Neglect Trop D. 2013;7(5):e2189. doi: 10.1371/journal.pntd.0002189.

758 Dana D, Vlaminck J, Ayana M, Tadege B, Mekonnen Z, Geldhof P, et al. Evaluation of 37. 759 copromicroscopy and serology to measure the exposure to Ascaris infections across age 760 groups and to assess the impact of 3 years of biannual mass drug administration in Jimma 761 Town, Ethiopia. Plos Neglect Trop D. 2020;14(4):e0008037. doi: 762 10.1371/journal.pntd.0008037.

38. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand
J Gastroenterol. 1997;32(9):920-4. Epub 1997/09/23. doi: 10.3109/00365529709011203.
PubMed PMID: 9299672.

Bosch F, Palmeirim MS, Ali SM, Ame SM, Hattendorf J, Keiser J. Diagnosis of soiltransmitted helminths using the Kato-Katz technique: What is the influence of stirring, storage
time and storage temperature on stool sample egg counts? PLoS Negl Trop Dis.
2021;15(1):e0009032. Epub 2021/01/23. doi: 10.1371/journal.pntd.0009032. PubMed PMID:
33481808; PubMed Central PMCID: PMCPMC7857572.

771 40. Vlaminck J, Cools P, Albonico M, Ame S, Avana M, Cringoli G, et al. Therapeutic efficacy 772 of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic methods. 2019/08/02. 773 PLoS Negl Trop Dis. 2019;13(8):e0007471. Epub doi: 774 10.1371/journal.pntd.0007471. PubMed PMID: 31369562.

Kazienga A, Levecke B, Leta GT, de Vlas SJ, Coffeng LE. A general framework to support
cost-efficient survey design choices for the control of soil-transmitted helminths when

deploying Kato-Katz thick smear. PLoS Negl Trop Dis. 2023;17(6):e0011160. Epub 2023/06/22.

778 doi: 10.1371/journal.pntd.0011160. PubMed PMID: 37347783.

Kazienga A, Coffeng LE, de Vlas SJ, Levecke B. Two-stage lot quality assurance sampling
framework for monitoring and evaluation of neglected tropical diseases, allowing for
imperfect diagnostics and spatial heterogeneity. PLoS Negl Trop Dis. 2022;16(4):e0010353.
Epub 2022/04/09. doi: 10.1371/journal.pntd.0010353. PubMed PMID: 35394996; PubMed
Central PMCID: PMCPMC9020685.

43. Lyon AR, Munson SA, Renn BN, Atkins DC, Pullmann MD, Friedman E, et al. Use of

785 Human-Centered Design to Improve Implementation of Evidence-Based Psychotherapies in

786 Low-Resource Communities: Protocol for Studies Applying a Framework to Assess Usability .

787 JMIR Res Protoc. 2019;8(10):e14990. Epub 2019/10/11. doi: 10.2196/14990. PubMed PMID:

788 31599736; PubMed Central PMCID: PMCPMC6819011.

789 44. Boren T, Ramey J. Thinking aloud: reconciling theory and practice. IEEE Transactions
790 on Professional Communication. 2000;43(3):261-78. doi: 10.1109/47.867942.

Montresor A, Crompton DWT, Hall A, Bundy DAP, Savioli L, World Health Organization.
Division of Control of Tropical Diseases S, et al. Guidelines for the evaluation of soiltransmitted helminthiasis and schistosomiasis at community level : a guide for managers of
control programmes. Geneva: World Health Organization; 1998.

Macefield R. How to specify the participant group size for usability studies: a
practitioner's guide. Journal of Usability Studies archive. 2009;5:34-45.

797 47. Newcombe RG. Improved confidence intervals for the difference between binomial
798 proportions based on paired data. Stat Med. 1998;17(22):2635-50. Epub 1998/12/05.
799 PubMed PMID: 9839354.

48. Lewis FI, Torgerson PR. A tutorial in estimating the prevalence of disease in humans
and animals in the absence of a gold standard diagnostic. Emerging Themes in Epidemiology.
2012;9(1):9. doi: 10.1186/1742-7622-9-9.

49. Bärenbold O, Garba A, Colley DG, Fleming FM, Assaré RK, Tukahebwa EM, et al.
Estimating true prevalence of Schistosoma mansoni from population summary measures
based on the Kato-Katz diagnostic technique. Plos Neglect Trop D. 2021;15(4):e0009310. doi:
10.1371/journal.pntd.0009310.

Knopp S, Mgeni AF, Khamis IS, Steinmann P, Stothard JR, Rollinson D, et al. Diagnosis
of soil-transmitted helminths in the era of preventive chemotherapy: Effect of multiple stool
sampling and use of different diagnostic techniques. Plos Neglect Trop D. 2008;2(11). doi:
10.1371/journal.pntd.0000331.

S1. Glinz D, Silué KD, Knopp S, Lohourignon LK, Yao KP, Steinmann P, et al. Comparing
Diagnostic Accuracy of Kato-Katz, Koga Agar Plate, Ether-Concentration, and FLOTAC for
Schistosoma mansoni and Soil-Transmitted Helminths. Plos Neglect Trop D. 2010;4(7):e754.
doi: 10.1371/journal.pntd.0000754.

52. Jeandron A, Abdyldaieva G, Usubalieva J, Ensink JH, Cox J, Matthys B, et al. Accuracy
of the Kato-Katz, adhesive tape and FLOTAC techniques for helminth diagnosis among
children in Kyrgyzstan. Acta Trop. 2010;116(3):185-92. Epub 2010/08/31. doi:
10.1016/j.actatropica.2010.08.010. PubMed PMID: 20800568.

Booth M, Vounatsou P, N'Goran E K, Tanner M, Utzinger J. The influence of sampling
effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni
and hookworm co-infections in rural Côte d'Ivoire. Parasitology. 2003;127(Pt 6):525-31. Epub
2004/01/01. doi: 10.1017/s0031182003004128. PubMed PMID: 14700188.

54. Gass K. Time for a diagnostic sea-change: Rethinking neglected tropical disease
diagnostics to achieve elimination. Plos Neglect Trop D. 2021;14(12):e0008933. doi:
10.1371/journal.pntd.0008933.

- 826 55. Ásbjörnsdóttir KH, Ajjampur SSR, Anderson RM, Bailey R, Gardiner I, Halliday KE, et al.
- 827 Assessing the feasibility of interrupting the transmission of soil-transmitted helminths
- 828 through mass drug administration: The DeWorm3 cluster randomized trial protocol. PLoS
- Negl Trop Dis. 2018;12(1):e0006166. Epub 2018/01/19. doi: 10.1371/journal.pntd.0006166.
- 830 PubMed PMID: 29346377; PubMed Central PMCID: PMCPMC5773085.

831 Supplementary info

- 832 S1 Info. The methodology to determine the required sample sizes to test the project
- 833 hypotheses around diagnostic performance, repeatability, and reproducibility.
- 834 S2. Info. Detailed overview of how our current AI-DP already meets the attributes defined
- in the WHO TPP criteria, and for which attributes this study will provide full, partial or no

836 evidence.

837

838 Funding

839 This study will be financially supported by a Johnson & Johnson Foundation project (Funder:

Johnson & Johnson Foundation Scotland, Grantee: Enaiblers AB, ID: 76906491). The funding

841 body did not have any role in the writing of this manuscript.

842

843 Acknowledgements

844 We are extremely grateful to Dr. Lieven Stuyver (Janssen Global Public Health, Janssen R&D,

845 2340 Beerse, Belgium) for initiating the concept of an AI-DP for NTDS, and to continue steering

846 multi-disciplinary teams worldwide towards a proof-principle for the AI-DP described in this

847 work.



electronic data capture QR-code printing sample collection KK thick smear preparation slide loading boundary confirmation automated slide scanning egg identification and quantification Al-determinants confirmation







